A FIRST-IN-HUMAN STUDY OF THE SECOND-GENERATION, THIN-STRUT, EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: 6-MONTH IVUS AND OCT RESULTS FROM THE FAST CLINICAL TRIAL

Ryo Kameda,Kozo Okada,Masayasu Ikutomi,M. Brooke Hollak,Paul G. Yock,Jeffrey Popma,Sujith Seneviratne,Andrejs Erglis,Darren Walters,Robert Whitbourn,Jamie Layland,James R. Stewart,Seif El-Jack,Thomas Christen,Ian Meredith,Peter J. Fitzgerald,Yasuhiro Honda

A FIRST-IN-HUMAN STUDY OF THE SECOND-GENERATION, THIN-STRUT, EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: 6-MONTH IVUS AND OCT RESULTS FROM THE FAST CLINICAL TRIAL

2019

Ryo Kameda
Kozo Okada
Masayasu Ikutomi
M. Brooke Hollak
Paul G. Yock
Jeffrey Popma
Sujith Seneviratne
Andrejs Erglis
Darren Walters
Robert Whitbourn
Jamie Layland
James R. Stewart
Seif El-Jack
Thomas Christen
Ian Meredith
Peter J. Fitzgerald
Yasuhiro Honda

In second-generation bioresorbable scaffolds, thinner struts are often adopted to improve both deliverability and safety profiles, while theoretical concerns remain regarding radial strength and fracture resistance. This analysis aimed to evaluate acute and mid-term performance of the RENUVIA

Keywords:

Clinical trial
Cardiology
Radiology
Scaffold
Everolimus
Human study
Medicine
Internal medicine
first in human
bioresorbable scaffold

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations